Literature DB >> 26941260

Stroke and Embolic Events in Hypertrophic Cardiomyopathy: Risk Stratification in Patients Without Atrial Fibrillation.

Shintaro Haruki1, Yuichiro Minami2, Nobuhisa Hagiwara1.   

Abstract

BACKGROUND AND
PURPOSE: Stroke and systemic embolic events are known to occur as complications of hypertrophic cardiomyopathy (HCM), and these complications are more common in patients with accompanying atrial fibrillation (AF). The diagnosis of AF is sometimes difficult, however, and it is possible that subclinical asymptomatic paroxysmal episodes or a first episode of AF in patients without previously documented AF may lead to embolic events. We investigated the prevalence of embolic events in patients with HCM and evaluated risk factors for these events in patients without documented AF.
METHODS: This study enrolled 593 patients with clinically diagnosed HCM (age at diagnosis, 51.0±15.6 years) from 1980 to 2010.
RESULTS: During a mean follow-up of 10.7±7.5 years, 68 (11.5%) experienced stroke and embolic events. AF had been documented before the event in 29 (42.6%) of them. AF was documented for the first time at the time of the event in 5 (7.4%) and after the event in 10 (14.7%). Among the 431 patients without previously documented AF (39 with events and 392 without events), older age at diagnosis and left atrial dimension ≥48 mm were identified as the independent determinants of the embolic event after adjusting for sex and classic prognostic markers related to HCM.
CONCLUSIONS: The incidence of stroke and embolic events was about 1.0% per year in the HCM cohort. AF had not been previously documented before the event in more than half of patients with events. Older age and enlarged left atrial dimension are possible risk factors for embolic events in patients with HCM without documented AF.
© 2016 American Heart Association, Inc.

Entities:  

Keywords:  atrial fibrillation; cardiomyopathies; heart atria; risk factors; stroke

Mesh:

Year:  2016        PMID: 26941260     DOI: 10.1161/STROKEAHA.115.012130

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  14 in total

1.  Prognostic impact of atrial fibrillation in hypertrophic cardiomyopathy: a systematic review.

Authors:  Patricia Alphonse; Sohaib Virk; Jhonna Collins; Timothy Campbell; Stuart P Thomas; Christopher Semsarian; Saurabh Kumar
Journal:  Clin Res Cardiol       Date:  2020-09-03       Impact factor: 5.460

2.  Atrial Fibrillation and Anticoagulation in Hypertrophic Cardiomyopathy.

Authors:  C Fielder Camm; A John Camm
Journal:  Arrhythm Electrophysiol Rev       Date:  2017-06

Review 3.  Atrial Fibrillation in Hypertrophic Cardiomyopathy: Diagnosis and Considerations for Management.

Authors:  Monica Patten; Simon Pecha; Ali Aydin
Journal:  J Atr Fibrillation       Date:  2018-02-28

Review 4.  Ischaemic events in hypertrophic cardiomyopathy patients with and without atrial fibrillation: a systematic review and meta-analysis.

Authors:  Tiffany T S Ye; Qi Zhuang Siah; Benjamin Y Q Tan; Jamie S Y Ho; Nicholas L X Syn; Yao Hao Teo; Yao Neng Teo; James W Yip; Tiong-Cheng Yeo; Weiqin Lin; Raymond C C Wong; Ping Chai; Bernard Chan; Vijay Kumar Sharma; Leonard L L Yeo; Ching-Hui Sia
Journal:  J Thromb Thrombolysis       Date:  2022-10-03       Impact factor: 5.221

5.  Augmented risk of dementia in hypertrophic cardiomyopathy: A propensity score matching analysis using the nationwide cohort.

Authors:  Heesun Lee; Hyung-Kwan Kim; Bongseong Kim; Kyungdo Han; Jun-Bean Park; In-Chang Hwang; Yeonyee E Yoon; Hyo Eun Park; Su-Yeon Choi; Yong-Jin Kim; Goo-Yeong Cho
Journal:  PLoS One       Date:  2022-06-16       Impact factor: 3.752

Review 6.  Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical impact, and management.

Authors:  Lohit Garg; Manasvi Gupta; Syed Rafay Ali Sabzwari; Sahil Agrawal; Manyoo Agarwal; Talha Nazir; Jeffrey Gordon; Babak Bozorgnia; Matthew W Martinez
Journal:  Heart Fail Rev       Date:  2019-03       Impact factor: 4.214

7.  Thromboembolic Outcomes of Different Anticoagulation Strategies for Patients with Atrial Fibrillation in the Setting of Hypertrophic Cardiomyopathy: A Systematic Review.

Authors:  Matthew R Lozier; Alexandra M Sanchez; John J Lee; Elie M Donath; Vicente E Font; Esteban Escolar
Journal:  J Atr Fibrillation       Date:  2019-12-31

8.  Stroke risk in hypertrophic cardiomyopathy patients with atrial fibrillation: a nationwide database study.

Authors:  Jung-Chi Hsu; Ya-Ting Huang; Lian-Yu Lin
Journal:  Aging (Albany NY)       Date:  2020-11-23       Impact factor: 5.682

Review 9.  Thromboembolism in Patients with Hypertrophic Cardiomyopathy.

Authors:  Lu Liu; Zheng Liu; Xiaoping Chen; Sen He
Journal:  Int J Med Sci       Date:  2021-01-01       Impact factor: 3.738

10.  Risk of ischemic stroke in patients with hypertrophic cardiomyopathy in the absence of atrial fibrillation - a nationwide cohort study.

Authors:  Ting-Tse Lin; Yen-Ling Sung; Tsung-Yu Ko; Chih-Kuo Lee; Lian-Yu Lin; Jimmy Ji-Ming Juang; Cho-Kai Wu
Journal:  Aging (Albany NY)       Date:  2019-12-02       Impact factor: 5.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.